Secukinumab is used in the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.
It is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation.
It is administered through subcutaneous injection every month.
In 2016, it sold €480 million in Europe.
Labs that test for drug level:
Labs that test for ADA titre: